IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 5, June 2023

The Role of Helicobacter Pylori Infection in Gastric Carcinoma Pathogenesis

Ramakant Bhosale[1] and Dr. Nagendra Pratap Mishra[2]
Research Scholar, Department of Biochemistry[1]
Research Guide, Department of Biochemistry[2]
Sunrise University, Alwar, Rajasthan, India

Abstract: *Gastric carcinoma is one of the prevalent types of cancer globally with a notable morbidity and mortality rate. Helicobacter pylori (H. pylori) infection has been established as a significant risk factor for gastric carcinoma. This paper reviews current literature on the role of H. pylori infection in the pathogenesis of gastric carcinoma, exploring molecular mechanisms and clinical implications. Furthermore, the paper discusses potential preventive and therapeutic strategies to combat gastric carcinoma associated with H. pylori infection.*

Keywords: Prognostic Implications, Histopathology, Resection Margins

I. INTRODUCTION

Gastric carcinoma, often referred to as stomach cancer, is a significant global health burden. The role of Helicobacter pylori, a Gram-negative bacterium that colonizes the stomach, in the onset and progression of gastric carcinoma has been extensively studied. H. pylori infection has been categorized as a Group 1 carcinogen for gastric cancer by the International Agency for Research on Cancer (IARC). Understanding the molecular mechanisms through which H. pylori contributes to gastric carcinoma pathogenesis is critical for the development of preventive and therapeutic strategies.

Gastric Premalignancy and the Critical Role of Inflammation

The pathogenesis of gastric malignancy often commences with a phase of premalignancy, where alterations within the gastric mucosa set the stage for subsequent malignant transformation. Central to this pre-malignant phase is the critical role played by inflammation, which is often triggered by infections, notably by Helicobacter pylori (H. pylori). The chronic inflammatory state induced by such infections brings about a milieu of cellular and molecular changes within the gastric epithelium and its microenvironment, significantly enhancing the risk of malignant transformation.

The chronic inflammation leads to a state of persistent oxidative stress and the production of reactive oxygen and nitrogen species, which in turn causes DNA damage, promoting genetic and epigenetic alterations within the gastric mucosal cells. Moreover, the inflammatory milieu recruits a host of immune cells, including macrophages and neutrophils, which not only further perpetuate the inflammatory state but also contribute to the generation of a pro-tumorigenic environment through the secretion of cytokines, growth factors, and pro-angiogenic factors.

Furthermore, the chronic inflammatory state facilitates epithelial-mesenchymal transition (EMT), a critical process in cancer progression and metastasis. The deregulation of signaling pathways such as NF-κB, STAT3, and Wnt/β-catenin, driven by the inflammatory mediators, plays a vital role in the progression from pre-malignant to malignant states in the gastric mucosa.

Additionally, the persistent inflammation alters the gastric microbial community, further exacerbating the inflammatory state and potentially enhancing the risk of gastric cancer. The disrupted microbial homeostasis can lead to a vicious cycle of inflammation, leading to further DNA damage and the promotion of a pro-carcinogenic environment.

Cause and Epidemiology of Gastric Cancer

Gastric cancer, commonly referred to as stomach cancer, is a complex disease influenced by various genetic, environmental, and lifestyle factors. The epidemiology of gastric cancer shows significant geographic variation, with

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 5, June 2023

higher incidence rates observed in East Asia, Eastern Europe, and South America. Helicobacter pylori (H. pylori) infection is recognized as a significant risk factor for gastric cancer, with the bacterium contributing to about 89% of non-cardia gastric cancers worldwide. Chronic infection with H. pylori leads to gastritis, which can progress to atrophic gastritis, intestinal metaplasia, dysplasia, and eventually, adenocarcinoma.

In addition to H. pylori infection, other risk factors include dietary practices such as the consumption of smoked meats and salt-preserved foods, tobacco smoking, and heavy alcohol consumption. There's also a familial tendency towards gastric cancer, indicating a genetic predisposition. Certain genetic conditions like hereditary diffuse gastric cancer (HDGC) and mutations in genes like CDH1 significantly elevate the risk of gastric cancer. Occupational exposure to certain carcinogens and asbestos also have been associated with a heightened risk of gastric cancer.

The epidemiology of gastric cancer is also influenced by socioeconomic factors. Individuals in lower socioeconomic groups or in regions with lower socio-economic status are generally at a higher risk, possibly due to limited access to fresh foods and a higher prevalence of H. pylori infection. Preventive measures like H. pylori eradication, dietary modifications, and smoking cessation, along with early detection and treatment, are essential steps towards reducing the global burden of gastric cancer. The understanding of the cause and epidemiology of gastric cancer is crucial for developing targeted prevention and early intervention strategies to mitigate the disease's impact on global health.

Gastric Cancer Host Genetics

Gastric cancer, also known as stomach cancer, has a complex etiology that comprises both environmental and genetic factors. Among the genetic factors, host genetics play a pivotal role in the susceptibility and progression of gastric cancer. Various genetic polymorphisms have been associated with an increased risk of gastric cancer. For instance, polymorphisms in genes involved in inflammatory and immune responses, such as Interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), have been correlated with gastric cancer risk. The genetic variations in these cytokine genes can influence the inflammatory milieu within the gastric mucosa, which in turn can promote carcinogenesis. Additionally, genetic alterations in genes responsible for DNA repair mechanisms, such as the mismatch repair (MMR) system and genes like TP53, have been identified in many gastric cancer patients. These genetic alterations can lead to genomic instability, facilitating the accumulation of mutations and the progression of gastric cancer. Furthermore, the hereditary diffuse gastric cancer (HDGC) syndrome, which is primarily associated with mutations in the CDH1 gene encoding E-cadherin, showcases a direct inherited genetic predisposition to gastric cancer. Genome-wide association studies (GWAS) have also identified several loci associated with an increased risk of gastric cancer, reflecting the polygenic nature of gastric cancer susceptibility. Moreover, the interaction between host genetics and environmental factors such as Helicobacter pylori infection further complicates the understanding of gastric cancer pathogenesis. Identifying and understanding the host genetic factors involved in gastric cancer is critical for developing risk stratification, early detection methods, and personalized therapeutic strategies to better manage and treat gastric cancer. Through ongoing research in this domain, there's an anticipation for the elucidation of more genetic markers that could significantly contribute to the prediction and prognosis of gastric cancer, opening avenues for more targeted and effective therapeutic interventions.

Gastric Cancer Pathology

Gastric cancer, or gastric carcinoma, primarily originates from the lining of the stomach and is often the result of prolonged inflammation and malignant transformation of epithelial cells. Pathologically, gastric cancer can be classified into several types, with adenocarcinoma being the most common, comprising about 90-95% of all gastric malignancies. Other subtypes include squamous cell carcinoma, lymphoma, and gastrointestinal stromal tumors. The pathogenesis of gastric cancer is multifaceted, with both genetic and environmental factors playing significant roles. Helicobacter pylori infection is a well-established environmental risk factor, leading to chronic gastritis, which over time, under a background of genetic predisposition, can progress to atrophic gastritis, intestinal metaplasia, dysplasia, and eventually adenocarcinoma. Other contributing factors include dietary habits, tobacco smoking, alcohol consumption, and certain inherited conditions. On a molecular level, alterations in several oncogenes, tumor suppressor genes, DNA mismatch repair genes, and cell cycle regulators have been identified in gastric cancer. The tumor, node, metastasis (TNM) staging system is commonly employed to stage gastric cancer, which is crucial for prognosis and determining the

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 5, June 2023

appropriate treatment strategy. Histologically, gastric cancer can further be classified based on its morphological appearance as per the Lauren classification into intestinal type, diffuse type, and mixed type, each having distinct pathological features and clinical outcomes. The intestinal type is often associated with well-formed glandular structures while the diffuse type is characterized by poorly cohesive, scattered tumor cells infiltrating the gastric wall. The understanding of gastric cancer's pathological mechanisms continues to evolve, offering hope for better diagnostic, prognostic, and therapeutic strategies to manage this often devastating disease.

Gene Mutations in Gastric Cancer

Gastric cancer is a complex disease characterized by the interplay of various genetic and environmental factors. Among the genetic elements, gene mutations play a pivotal role in the initiation and progression of gastric cancer. Several genes have been identified to harbor mutations which contribute to gastric carcinogenesis. For instance, mutations in the tumor suppressor gene TP53 are among the most common in gastric cancer, leading to the loss of control over cell cycle progression and apoptosis. Similarly, alterations in the CDH1 gene, which codes for E-cadherin, a protein crucial for cell adhesion, are associated with hereditary diffuse gastric cancer. Other notable genes include the oncogenes KRAS and HER2 (ERBB2), which when mutated or amplified, drive the aberrant activation of growth signaling pathways. Moreover, mutations in the mismatch repair genes like MLH1 and MSH2 result in microsatellite instability (MSI), a phenotype observed in a subset of gastric cancers. Recent advances in next-generation sequencing technologies have allowed for more comprehensive genomic analyses, uncovering additional mutated genes and altered pathways involved in gastric cancer such as the PI3K/Akt/mTOR and Wnt/β-catenin signaling pathways. Furthermore, alterations in the ARID1A, SMARCA4, and other genes involved in chromatin remodeling have also been associated with gastric cancer. Understanding the spectrum and role of gene mutations in gastric cancer not only sheds light on the molecular pathogenesis of the disease but also opens avenues for targeted therapeutic strategies. For example, HER2 amplification has become a predictive biomarker for the efficacy of trastuzumab, a targeted therapy in gastric cancer. As the genomic landscape of gastric cancer continues to be elucidated, personalized medicine based on the individual genetic makeup of the tumor is becoming a more achievable goal, holding promise for improving the prognosis and treatment outcomes for gastric cancer patients.

Gastric Cancer Transcriptome—Gene Signatures and Alternative Splicing

Gastric cancer transcriptomics is a burgeoning area of research aiming to elucidate the molecular underpinnings of gastric carcinogenesis and identify novel diagnostic and therapeutic targets. By examining the transcriptome, which encompasses the complete set of RNA transcripts produced by the genome under specific circumstances, insights into gene expression patterns and regulatory networks driving gastric cancer can be gleaned. One significant aspect of transcriptomic analysis is the identification of gene signatures, which are sets of genes whose expression levels collectively act as molecular indicators of certain biological or pathological states. In gastric cancer, gene signatures can provide crucial information regarding tumor classification, prognostication, and the prediction of treatment responses.

Additionally, transcriptomic studies have shed light on alternative splicing events in gastric cancer. Alternative splicing is a regulated process during gene expression that leads to a single gene coding for multiple proteins, thus adding a layer of complexity to the functional genomics of gastric cancer. Dysregulated alternative splicing has been implicated in various cancer-related processes such as cell proliferation, invasion, and resistance to apoptosis. In gastric cancer, specific splicing variants have been associated with tumor progression and patient prognosis, offering a potential avenue for the development of new therapeutic strategies.

The study of the gastric cancer transcriptome, encompassing gene signatures and alternative splicing, holds the promise of significantly advancing our understanding of gastric cancer pathogenesis. Through the integration of transcriptomic data with other omics technologies, a more comprehensive molecular landscape of gastric cancer can be constructed, potentially leading to the development of novel, targeted treatment approaches and improving patient outcomes in this devastating disease.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 5, June 2023

II. CONCLUSION

The relationship between H. pylori infection and gastric carcinoma is well-established, with the bacterium's virulence factors and the host's immune responses playing crucial roles in the cancer's pathogenesis. Early detection and eradication of H. pylori, along with the development of novel therapeutic strategies, could significantly reduce the incidence and mortality associated with gastric carcinoma.

REFERENCES

[1]. Ferlay JSI, Ervik M, Dikshit R, et al. International Agency for Research on Cancer, Cancer Incidence, and Mortality Worldwide. Lyon, France: IARC CancerBase no. 11, 2013.
[2]. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.
[3]. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–209.
[4]. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 1992;52:6735–6740.
[5]. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36–40.
[6]. Goldenring JR, Nomura S. Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and metaplasia. Am J Physiol Gastrointest Liver Physiol 2006;291:G999–1004.
[7]. Goldenring JR, Nam KT. Oxyntic atrophy, metaplasia, and gastric cancer. Dev Diff Dis 2010;96:117–131.
[8]. Karin M. Inflammation and cancer: the long reach of Ras. Nat Med 2005;11:20–21.
[9]. Eaton KA, Logan SM, Baker PE, et al. Helicobacter pylori with a truncated lipopolysaccharide O chain fails to induce gastritis in SCID mice injected with splenocytes from wild-type C57BL/6J mice. Infect Immun 2004; 72:3925–3931.
[10]. Lochhead P, El-Omar EM. Gastric cancer. Br Med Bull 2008;85:87–100.
[11]. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007;10:75–83.
[12]. Noto JM, Gaddy JA, Lee JY, et al. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest 2013;123:479–492.
[13]. Iwakiri D TK. Epstein-Barr virus and gastric cancers. In: ES R, ed. Epstein-Barr virus. Norfolk, VA: Caister Academic Press, 2005:157–169.
[14]. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 2009;137:824–833.
[15]. Peleteiro B, Bastos A, Ferro A, et al. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014; 59:1698–1709.
[16]. Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 2000;287:1497–1500.
[17]. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A 2008;105: 1003–1008.
[18]. Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A 2002;99:14428–14433.
[19]. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683–686.
[20]. Amieva MR, Vogelmann R, Covacci A, et al. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003;300:1430–1434.